Markets:

Overview

News

Currencies

International

Treasuries

Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

88.65 +0.85 (+0.97%)

Streaming Delayed Price Updated: 12:03 PM EDT, May 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Dianthus Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >

Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 ↗

April 19, 2026

This clinical-stage biotech focused on monoclonal antibody therapies reported a notable insider sale in its latest SEC filing.

Via The Motley Fool

Topics Regulatory Compliance

Dianthus Therapeutics CFO Sells $9.5 Million in Stock ↗

April 06, 2026

This biotech firm developing antibody therapies for rare diseases disclosed a significant insider sale amid rapid share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗

March 18, 2026

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

Via The Motley Fool

Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics ↗

December 20, 2024

Via Benzinga

Evaluating Dianthus Therapeutics: Insights From 5 Financial Analysts ↗

November 11, 2024

Via Benzinga

A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts ↗

November 08, 2024

Via Benzinga

Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough

March 12, 2026

Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal...

Via Finterra

Topics Economy

DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch ↗

March 09, 2026

Dianthus Therapeutics announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy program based on analysis of data from a part of...

Via Stocktwits

Gapping stocks in Monday's session ↗

March 09, 2026

Via Chartmill

Expert Ratings For Dianthus Therapeutics ↗

September 26, 2024

Via Benzinga

Navigating 4 Analyst Ratings For Dianthus Therapeutics ↗

August 12, 2024

Via Benzinga

What 5 Analyst Ratings Have To Say About Dianthus Therapeutics ↗

May 10, 2024

Via Benzinga

The Great Rotation: Small-Caps Break the Mega-Cap Monopoly in Early 2026

February 23, 2026

The financial landscape of 2026 has opened with a dramatic shift in market leadership, as small-cap stocks stage a historic rally that has left large-cap tech giants in the rearview mirror. After years...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run ↗

January 07, 2026

This biotech developing therapies for rare autoimmune diseases reported notable insider selling in its most recent SEC disclosure.

Via The Motley Fool

Topics Regulatory Compliance

General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday ↗

September 12, 2025

Via Benzinga

3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores ↗

September 12, 2025

A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores.

Via Benzinga

Analyst Expectations For Dianthus Therapeutics's Future ↗

September 09, 2025

Via Benzinga

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again ↗

September 08, 2025

The company is working on a treatment for an autoimmune disease that affects the muscles.

Via Investor's Business Daily

Dianthus Scores Early Success, Analyst Boosts Confidence In Broader Drug Pipeline ↗

September 08, 2025

Dianthus's claseprubart showed rapid, meaningful improvements in gMG symptoms with a favorable safety profile in Phase 2 MaGic trial results.

Via Benzinga

Top movers in Monday's pre-market session ↗

September 08, 2025

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 08, 2025

Via Benzinga

Dianthus Therapeutics Inc (NASDAQ:DNTH) Q2 2025 Earnings: Revenue Misses, EPS Meets Estimates ↗

August 07, 2025

Dianthus Therapeutics Q2 2025 earnings show revenue miss but EPS in line. Cash reserves strong, key clinical trials progressing with major data readouts expected in 2025-2026.

Via Chartmill

Dianthus (DNTH) Q2 Loss Widens 80% ↗

August 07, 2025

Via The Motley Fool

Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views ↗

May 13, 2025

Via Benzinga

Friday's pre-market session: top gainers and losers ↗

April 04, 2025

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

April 04, 2025

Via Benzinga

Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

November 20, 2024

Via Benzinga

Ulta Beauty Reports Downbeat Results, Joins Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

August 30, 2024

Via Benzinga

DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 09, 2024

DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

DNTH stock results show that Dianthus Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.